Author pages are created from data sourced from our academic publisher partnerships and public sources.
A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo
ABSTRACT Mathematical models provide an understanding of in vivo replication kinetics of human immunodeficiency virus type 1 (HIV-1). With a novel intervention designed for increased potency, we have… Expand
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
BACKGROUND Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir concentrations that are at… Expand
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
- D. Kempf, K. Marsh, +12 authors J. Leonard
- Biology, Medicine
- Antimicrobial agents and chemotherapy
- 1 March 1997
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for enhancing the levels of other peptidomimetic HIV protease inhibitors in… Expand
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease…
ABSTRACT The association of genotypic changes in human immunodeficiency virus (HIV) protease with reduced in vitro susceptibility to the new protease inhibitor lopinavir (previously ABT-378) was… Expand
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
ObjectiveTo evaluate the safety and antiviral activity of different dose levels of the HIV protease inhibitor ABT-378 combined with low-dose ritonavir, plus stavudine and lamivudine in… Expand
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
- X. Sáez-Llorens, A. Violari, +17 authors E. Sun
- The Pediatric infectious disease journal
- 1 March 2003
Background. Lopinavir/ritonavir has demonstrated antiviral activity in the HIV-infected adult. Subjects. The objective of this study was to investigate a liquid coformulation of lopinavir/ritonavir,… Expand
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study
- J. Pullman, J. Gardovskis, +5 authors S. Cammarata
- The Journal of antimicrobial chemotherapy
- 5 October 2017
Abstract Background Delafloxacin is an investigational anionic fluoroquinolone in development for oral or intravenous administration for the treatment of infections caused by Gram-positive (including… Expand
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Study M98-863 was a double-blind, randomized, phase 3 study that compared lopinavir/ritonavir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-naive… Expand
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
- H. Sham, D. Kempf, +24 authors D. Norbeck
- Biology, Medicine
- Antimicrobial Agents and Chemotherapy
- 1 December 1998
ABSTRACT The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using the… Expand
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *
- A. Hsu, G. R. Granneman, +7 authors J. Leonard
- Chemistry, Medicine
- Clinical pharmacology and therapeutics
- 1 April 1998
To assess the pharmacokinetic interaction between ritonavir and saquinavir.